Merck KGaA

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Merck KGaA (MKKGY) a Great Value Stock Right Now?

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 was mixed-positive. Going into Q3 2024, I consider MKGAF to be an attractive "Buy" with an attractive price target of €175/share. Read what you could get by investing in Merck KGaA and why this company has an upside of at least 14.5% (as I consider it).

Merck KGaA: A Continued Long-Term Upside Despite Some Lag

The German company said booming artificial-intelligence demand would help its electronics sales grow faster than previously expected over the medium term.

Merck KGaA Shares Jump on Expectations of AI Boost

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the first patient has been dosed in the Phase III MyClad trial (NCT06463587) evaluating the efficacy and safety of oral cladribine for the treatment of generalized Myasthenia Gravis (gMG). Cladribine capsules have the potential to be the first oral treatment for gMG patients. gMG is a rare, neuromuscular disorder causing muscle weakness that can be severe and have a sig.

Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (OTCPK:MKGAF) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Lopez - Chair of Executive Board & CEO Helene von Roeder - CFO Peter Guenter - CEO of Healthcare Business Matthias Heinzel - CEO of Life Science Sector Kai Beckmann - CEO of Electronics Conference Call Participants Richard Vosser - JPMorgan Sachin Jain - Bank of America Peter Verdult - Citi Thibault Boutherin - Morgan Stanley Falko Friedrichs - Deutsche Bank Oliver Metzger - Oddo BHF Gary Steventon - BNP Paribas Exane Florent Cespedes - Bernstein Simon Baker - Redburn Atlantic Constantin Fest A very warm welcome from my side to this Merck Q2 2024 Results Call. My name is Constantin Fest, I'm Head of Investor Relations here at Merck.

Merck KGaA (MKGAF) Q2 2024 Earnings Call Transcript

Merck KGaA remains undervalued with strong fundamentals and diverse business portfolio in healthcare, life sciences, and electronics. The company has above-average margins compared to the broader market, indicating outperformance potential. Despite volatility, Merck KGaA presents an interesting upside for investors.

Merck KGaA: The Drop Makes The Upside All The Sweeter

Merck KGaA shares fell by as much as 10% after the company announced the termination of its phase III trial of xevinapant in neck cancer. The interim analysis revealed that the study is unlikely to meet its primary objective, prompting the halt.

Merck KGaA shares slump on neck cancer trial failure

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). The decision follows a pre-planned interim analysis performed by the study's Independent Data Monitoring Committee, which found that the trial would be unlik.

Merck KGaA, Darmstadt, Germany, Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced new research from the company's diverse oncology portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4, Chicago. Data from company- and investigator-sponsored studies include 31 accepted abstracts across more than 10 tumor types, including seven oral presentations, highlighting the company's innovative oncology pipeline encompassin.

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024

Merck KGaA (OTCPK:MKGAF) Q1 2024 Results Conference Call May 15, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO Matthias Heinzel - CEO, Life Science Sector Peter Guenter - CEO, Healthcare Business Kai Beckmann - CEO, Electronics Conference Call Participants Sachin Jain - Bank of America Richard Vosser - JPMorgan Colin White - UBS Peter Verdult - Citi Emily Field - Barclays Thibault Boutherin - Morgan Stanley Oliver Metzger - ODDO BHF Ed Hall - Stifel Gary Steventon - BNP Paribas Exane Rajesh Kumar - HSBC Simon Baker - Redburn Atlantic Florent Cespedes - Bernstein Operator Dear ladies and gentlemen, welcome to the Merck Investor and Analyst Conference Call on the First Quarter 2024. As a reminder, all participants will be in a listen-only mode.

Merck KGaA (MKGAF) Q1 2024 Earnings Call Transcript

Merck KGaA on Wednesday reported better-than-expected adjusted earnings, helped by strong demand for its pharmaceuticals and amid currency-adjusted sales growth in semiconductor materials.

Merck KGaA's Q1 adjusted profit declines less than feared

Merck KGaA (OTCPK:MKGAF) Q4 2023 Results Conference Call March 7, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO Matthias Heinzel - CEO, Life Science Sector Peter Guenter - CEO, Healthcare Business Kai Beckmann - CEO, Electronics Conference Call Participants Colin White - UBS Sophia Gray - JPMorgan Charlie Hayward - Bank of America Falko Friedrichs - Deutsche Bank Gary Steventon - BNP Paribas, Exane Edward Hall - Stifel Oliver Metzger - ODDO BHF Operator Dear ladies and gentlemen, welcome to the Merck Investor and Analyst Conference Call on the Fourth Quarter 2023. As a reminder, all participants will be in a listen-only mode.

Merck KGaA (MKGAF) Q4 2023 Earnings Call Transcript

Merck KGaA predicted a return to modest operating earnings growth, when adjusted for currency headwinds, citing a gradual recovery in demand for specialty materials that are used to make biotech drugs and semiconductors.

Merck KGaA forecasts return to organic earnings growth in 2024

Merck KGaA shares plunged more than 12% on Wednesday after the company announced that its experimental multiple sclerosis (MS) drug evobrutinib failed to meet the primary endpoint in Phase 3 clinical trials. The company said that its drug did not reduce the annualized relapse rates in people with relapsing MS when compared to Sanofi's oral teriflunomide.

Merck KGaA's experimental MS drug fails in late stage trials sending shares tumbling

Germany's Merck KGaA said on Tuesday the company's experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials.

Merck KGaA says MS drug fails in late-stage trials

Germany's diversified group Merck KGaA reported a 20% decline in quarterly operating profit on weak demand for specialty materials that are used to make biotech drugs and semiconductors.

Merck KGaA Q3 earnings down 20% on weak biotech, electronics demand

Merck KGaA is an undervalued pharma company with a long history and strong fundamentals. The company has above-average margins and a diverse business portfolio in healthcare, life sciences, and electronics. Despite a conservative dividend yield, Merck KGaA has potential for long-term growth and a target price of at least €180/share.

Merck KGaA: Company With A Potential Upside

Germany's Merck KGaA on Monday said it struck a collaboration deal with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to widen Merck's work in an area known as "DNA damage response" drugs.

Merck KGaA widens work on 'DNA damage' drugs in deal with China's Hengrui

The CEO of Germany's Merck KGaA said the company's experimental multiple sclerosis drug can be a "blockbuster", an industry term for annual sales that exceed $1 billion, even after concerns emerged that it may cause liver damage.

Merck KGaA says MS drug has blockbuster potential; key data expected in December

Germany's diversified group Merck KGaA has raised the prospect of returning to revenue growth next year, recovering from a slump in demand for its specialty materials to produce biotech drugs and semiconductors.

Merck KGaA raises prospect of return to sales growth next year

ExScientia Ltd

Frontier IP Group PLC (AIM:FIPP), a firm specialising in the commercialisation of intellectual property, announced in an RNS today that its portfolio company Exscientia has entered into a collaboration with Merck to discover novel small molecule drug candidates in the fields of oncology, neuroinflammation, and immunology. Under the terms of the agreement, Exscientia will receive an upfront payment of $20 million from Merck.

Frontier portfolio company signs collaboration deal with Merck

Exscientia PLC shares climbed as much as 30% in pre-market trading on Wednesday after the precision-medicine company announced a new, multi-year collaboration with German science and technology company Merck KGaA, which could be worth hundreds of millions of dollars.  The collaboration will involve using Exscientia's AI-driven precision drug design and discovery capabilities to discover novel small-molecule drug candidates across oncology, neuroinflammation and immunology, according to the company.

Exscientia stock surges on Merck KGaA partnership

The U.S.-listed shares of Exscientia PLC EXAI soared 28.5% toward a record one-day gain, and enough to pace all premarket gainers on major U.S. exchanges, after the U.K.-based precision medicine company announced a collaboration with Germany-based Merck KGaA MKKGY XE:MRK for the discovery of drug candidates across oncology, neuroinflammation and immunology. The multi-year collaboration will utilize Exscientia's drug design and discovery capabilities, which are driven by use of artificial intelligence.

Exscientia's stock rockets toward a record gain after AI-driven drug discovery collaboration with Germany's Merck KGaA

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company's research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., are expected to generate several novel clinical development drug candidates with first-in-class and best-in-class pote.

Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

Merck KGaA reported disappointing Q2 results with a decrease in gross profit and EBIT compared to the previous year. The company remains confident in its 2025 targets despite reducing its full-year guidance for 2023. Anticipated double-digit revenue growth in 2024 and 2025 makes Merck a potential investment opportunity.

News for Merck KGaA Stock (MKKGY)